NCT03219047View on ClinicalTrials.gov

Patient-Derived Xenografts in Personalizing Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

December 20, 2018

Primary Completion Date

July 3, 2023

Study Completion Date

July 3, 2023

Conditions
Recurrent Mantle Cell LymphomaRefractory Mantle Cell Lymphoma
Interventions
OTHER

Best Practice

Receive standard of care

DRUG

Ibrutinib

Given at standard dose and schedule

OTHER

Patient Derived Xenograft

Xenograft developed

OTHER

Personalized Medicine

Receive treatment based on the results of the PDX models

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT03219047 - Patient-Derived Xenografts in Personalizing Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma | Biotech Hunter | Biotech Hunter